Inactive Instrument

Company Merrimack Pharmaceuticals Inc Nasdaq

Equities

US5903281005

Biotechnology & Medical Research

Business Summary

Merrimack Pharmaceuticals, Inc. is a biopharmaceutical company. The Company does not have any ongoing research or development activities and is seeking potential acquirers for its remaining preclinical and clinical assets. It is entitled to receive payments related to its sale of ONIVYDE to Ipsen S.A. and also its contingent payments related to its sale of MM-121 and MM-111 to Elevation Oncology, Inc. These payments are payable by Ipsen upon approval by the United States Food and Drug Administration (FDA) of Onivyde for certain additional clinical indications. ONIVYDE is approved by FDA to market as a first-line treatment of metastatic adenocarcinoma on the pancreas. It is also entitled to receive payments related to its sale of anti-HER3 programs to Elevation Oncology, Inc. The Company’s wholly owned subsidiaries include Merrimack Pharmaceuticals UK Limited and Merrimack Securities Corporation.

Managers

Managers TitleAgeSince
Founder 52 01/93/01
Chief Executive Officer 72 01/04/01
Investor Relations Contact - -

Members of the board

Members of the board TitleAgeSince
Chief Executive Officer 72 01/04/01
Director/Board Member 45 19/19/19
Founder 52 01/93/01
Director/Board Member 46 19/19/19
Director/Board Member 44 06/22/06

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 14,788,369 14,612,210 ( 98.81 %) 0 98.81 %

Company contact information

Merrimack Pharmaceuticals, Inc.

One Broadway 14th Floor

02142, Cambridge

+

http://www.merrimackpharma.com
address Merrimack Pharmaceuticals Inc
  1. Stock Market
  2. Equities
  3. MACK Stock
  4. Stock
  5. Company Merrimack Pharmaceuticals Inc